Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents
Identifieur interne : 002134 ( Istex/Corpus ); précédent : 002133; suivant : 002135Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents
Auteurs : Rossana Scrivo ; Ilaria Sauzullo ; Fabio Mengoni ; Giancarlo Iaiani ; Anna Rita Vestri ; Roberta Priori ; Elisa Di Filippo ; Manuela Di Franco ; Francesca Romana Spinelli ; Vincenzo Vullo ; Claudio Maria Mastroianni ; Guido ValesiniSource :
- Clinical Rheumatology [ 0770-3198 ] ; 2012-11-01.
English descriptors
Abstract
Abstract: Screening for latent tuberculosis infection (LTBI) prior to the prescribing of anti-TNF agents and monitoring for infection during treatment are recommended. The feasibility of novel screening tools, including QuantiFERON-TB Gold In-Tube (QFT-GIT), remains unclear in the setting of immunosuppression. The aim of this study was to evaluate the usefulness of serial QFT-GIT during biologic therapy to assess whether dynamic changes in IFN-γ levels may be helpful in identifying reactivation of LTBI or newly acquired TB. We conducted a prospective study on patient candidates to TNF inhibitors. QFT-GIT was performed at baseline and after 3 and 6 months since biologic onset. A further follow-up period of 6 months was observed. Among patients enrolled (n = 119; F = 69 %; median age = 47 years, range 18–80), 24 had at least 1 risk factor for LTBI. Ninety-six were taking immunosuppressants at the time of TB testing. At baseline, 5 patients displayed positive, 93 negative, and 21 indeterminate QFT-GIT results. We observed QFT-GIT conversions and reversions in 12 patients with LTBI and in 73 without LTBI. QFT-GIT results changed of 28 % at month 3 and of 21 % at month 6; the greatest change was observed in patients with indeterminate results that became negative (15 %; p < 0.02). No TB cases were detected. In conclusion, the routine use of both QFT-GIT and TST at screening seems not to give any advantage in the setting of patients awaiting biologics. In addition, the feasibility of serial QFT-GIT during biologic therapy needs definition since changes in IFN-γ levels may occur without a pathologic connotation.
Url:
DOI: 10.1007/s10067-012-2049-6
Links to Exploration step
ISTEX:71D2D40BFB93858AC2F628A3655E1297C173E8E5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title><author><name sortKey="Scrivo, Rossana" sort="Scrivo, Rossana" uniqKey="Scrivo R" first="Rossana" last="Scrivo">Rossana Scrivo</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: rossana.scrivo@uniroma1.it</mods:affiliation></affiliation></author><author><name sortKey="Sauzullo, Ilaria" sort="Sauzullo, Ilaria" uniqKey="Sauzullo I" first="Ilaria" last="Sauzullo">Ilaria Sauzullo</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mengoni, Fabio" sort="Mengoni, Fabio" uniqKey="Mengoni F" first="Fabio" last="Mengoni">Fabio Mengoni</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Iaiani, Giancarlo" sort="Iaiani, Giancarlo" uniqKey="Iaiani G" first="Giancarlo" last="Iaiani">Giancarlo Iaiani</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Vestri, Anna Rita" sort="Vestri, Anna Rita" uniqKey="Vestri A" first="Anna Rita" last="Vestri">Anna Rita Vestri</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Priori, Roberta" sort="Priori, Roberta" uniqKey="Priori R" first="Roberta" last="Priori">Roberta Priori</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Di Filippo, Elisa" sort="Di Filippo, Elisa" uniqKey="Di Filippo E" first="Elisa" last="Di Filippo">Elisa Di Filippo</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Di Franco, Manuela" sort="Di Franco, Manuela" uniqKey="Di Franco M" first="Manuela" last="Di Franco">Manuela Di Franco</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Spinelli, Francesca Romana" sort="Spinelli, Francesca Romana" uniqKey="Spinelli F" first="Francesca Romana" last="Spinelli">Francesca Romana Spinelli</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Vullo, Vincenzo" sort="Vullo, Vincenzo" uniqKey="Vullo V" first="Vincenzo" last="Vullo">Vincenzo Vullo</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mastroianni, Claudio Maria" sort="Mastroianni, Claudio Maria" uniqKey="Mastroianni C" first="Claudio Maria" last="Mastroianni">Claudio Maria Mastroianni</name><affiliation><mods:affiliation>UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza Università di Roma (Polo Pontino), Latina, Italy</mods:affiliation></affiliation></author><author><name sortKey="Valesini, Guido" sort="Valesini, Guido" uniqKey="Valesini G" first="Guido" last="Valesini">Guido Valesini</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:71D2D40BFB93858AC2F628A3655E1297C173E8E5</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1007/s10067-012-2049-6</idno><idno type="url">https://api.istex.fr/ark:/67375/VQC-PS6N8XWG-0/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002134</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002134</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title><author><name sortKey="Scrivo, Rossana" sort="Scrivo, Rossana" uniqKey="Scrivo R" first="Rossana" last="Scrivo">Rossana Scrivo</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: rossana.scrivo@uniroma1.it</mods:affiliation></affiliation></author><author><name sortKey="Sauzullo, Ilaria" sort="Sauzullo, Ilaria" uniqKey="Sauzullo I" first="Ilaria" last="Sauzullo">Ilaria Sauzullo</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mengoni, Fabio" sort="Mengoni, Fabio" uniqKey="Mengoni F" first="Fabio" last="Mengoni">Fabio Mengoni</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Iaiani, Giancarlo" sort="Iaiani, Giancarlo" uniqKey="Iaiani G" first="Giancarlo" last="Iaiani">Giancarlo Iaiani</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Vestri, Anna Rita" sort="Vestri, Anna Rita" uniqKey="Vestri A" first="Anna Rita" last="Vestri">Anna Rita Vestri</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Priori, Roberta" sort="Priori, Roberta" uniqKey="Priori R" first="Roberta" last="Priori">Roberta Priori</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Di Filippo, Elisa" sort="Di Filippo, Elisa" uniqKey="Di Filippo E" first="Elisa" last="Di Filippo">Elisa Di Filippo</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Di Franco, Manuela" sort="Di Franco, Manuela" uniqKey="Di Franco M" first="Manuela" last="Di Franco">Manuela Di Franco</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Spinelli, Francesca Romana" sort="Spinelli, Francesca Romana" uniqKey="Spinelli F" first="Francesca Romana" last="Spinelli">Francesca Romana Spinelli</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Vullo, Vincenzo" sort="Vullo, Vincenzo" uniqKey="Vullo V" first="Vincenzo" last="Vullo">Vincenzo Vullo</name><affiliation><mods:affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</mods:affiliation></affiliation></author><author><name sortKey="Mastroianni, Claudio Maria" sort="Mastroianni, Claudio Maria" uniqKey="Mastroianni C" first="Claudio Maria" last="Mastroianni">Claudio Maria Mastroianni</name><affiliation><mods:affiliation>UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza Università di Roma (Polo Pontino), Latina, Italy</mods:affiliation></affiliation></author><author><name sortKey="Valesini, Guido" sort="Valesini, Guido" uniqKey="Valesini G" first="Guido" last="Valesini">Guido Valesini</name><affiliation><mods:affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="ISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2012-11-01">2012-11-01</date><biblScope unit="volume">31</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1567">1567</biblScope><biblScope unit="page" to="1575">1575</biblScope></imprint><idno type="ISSN">0770-3198</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0770-3198</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-TNF</term><term>QuantiFERON-TB Gold In-Tube</term><term>Rheumatoid arthritis</term><term>Tuberculin skin test</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Screening for latent tuberculosis infection (LTBI) prior to the prescribing of anti-TNF agents and monitoring for infection during treatment are recommended. The feasibility of novel screening tools, including QuantiFERON-TB Gold In-Tube (QFT-GIT), remains unclear in the setting of immunosuppression. The aim of this study was to evaluate the usefulness of serial QFT-GIT during biologic therapy to assess whether dynamic changes in IFN-γ levels may be helpful in identifying reactivation of LTBI or newly acquired TB. We conducted a prospective study on patient candidates to TNF inhibitors. QFT-GIT was performed at baseline and after 3 and 6 months since biologic onset. A further follow-up period of 6 months was observed. Among patients enrolled (n = 119; F = 69 %; median age = 47 years, range 18–80), 24 had at least 1 risk factor for LTBI. Ninety-six were taking immunosuppressants at the time of TB testing. At baseline, 5 patients displayed positive, 93 negative, and 21 indeterminate QFT-GIT results. We observed QFT-GIT conversions and reversions in 12 patients with LTBI and in 73 without LTBI. QFT-GIT results changed of 28 % at month 3 and of 21 % at month 6; the greatest change was observed in patients with indeterminate results that became negative (15 %; p < 0.02). No TB cases were detected. In conclusion, the routine use of both QFT-GIT and TST at screening seems not to give any advantage in the setting of patients awaiting biologics. In addition, the feasibility of serial QFT-GIT during biologic therapy needs definition since changes in IFN-γ levels may occur without a pathologic connotation.</div></front></TEI><istex><corpusName>springer-journals</corpusName><author><json:item><name>Rossana Scrivo</name><affiliations><json:string>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</json:string><json:string>E-mail: rossana.scrivo@uniroma1.it</json:string></affiliations></json:item><json:item><name>Ilaria Sauzullo</name><affiliations><json:string>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</json:string></affiliations></json:item><json:item><name>Fabio Mengoni</name><affiliations><json:string>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</json:string></affiliations></json:item><json:item><name>Giancarlo Iaiani</name><affiliations><json:string>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</json:string></affiliations></json:item><json:item><name>Anna Rita Vestri</name><affiliations><json:string>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</json:string></affiliations></json:item><json:item><name>Roberta Priori</name><affiliations><json:string>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</json:string></affiliations></json:item><json:item><name>Elisa Di Filippo</name><affiliations><json:string>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</json:string></affiliations></json:item><json:item><name>Manuela Di Franco</name><affiliations><json:string>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</json:string></affiliations></json:item><json:item><name>Francesca Romana Spinelli</name><affiliations><json:string>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</json:string></affiliations></json:item><json:item><name>Vincenzo Vullo</name><affiliations><json:string>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</json:string></affiliations></json:item><json:item><name>Claudio Maria Mastroianni</name><affiliations><json:string>UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza Università di Roma (Polo Pontino), Latina, Italy</json:string></affiliations></json:item><json:item><name>Guido Valesini</name><affiliations><json:string>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Anti-TNF</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>QuantiFERON-TB Gold In-Tube</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Rheumatoid arthritis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Tuberculin skin test</value></json:item></subject><articleId><json:string>2049</json:string><json:string>s10067-012-2049-6</json:string></articleId><arkIstex>ark:/67375/VQC-PS6N8XWG-0</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>OriginalPaper</json:string></originalGenre><abstract>Abstract: Screening for latent tuberculosis infection (LTBI) prior to the prescribing of anti-TNF agents and monitoring for infection during treatment are recommended. The feasibility of novel screening tools, including QuantiFERON-TB Gold In-Tube (QFT-GIT), remains unclear in the setting of immunosuppression. The aim of this study was to evaluate the usefulness of serial QFT-GIT during biologic therapy to assess whether dynamic changes in IFN-γ levels may be helpful in identifying reactivation of LTBI or newly acquired TB. We conducted a prospective study on patient candidates to TNF inhibitors. QFT-GIT was performed at baseline and after 3 and 6 months since biologic onset. A further follow-up period of 6 months was observed. Among patients enrolled (n = 119; F = 69 %; median age = 47 years, range 18–80), 24 had at least 1 risk factor for LTBI. Ninety-six were taking immunosuppressants at the time of TB testing. At baseline, 5 patients displayed positive, 93 negative, and 21 indeterminate QFT-GIT results. We observed QFT-GIT conversions and reversions in 12 patients with LTBI and in 73 without LTBI. QFT-GIT results changed of 28 % at month 3 and of 21 % at month 6; the greatest change was observed in patients with indeterminate results that became negative (15 %; p > 0.02). No TB cases were detected. In conclusion, the routine use of both QFT-GIT and TST at screening seems not to give any advantage in the setting of patients awaiting biologics. In addition, the feasibility of serial QFT-GIT during biologic therapy needs definition since changes in IFN-γ levels may occur without a pathologic connotation.</abstract><qualityIndicators><score>9.94</score><pdfWordCount>5395</pdfWordCount><pdfCharCount>35203</pdfCharCount><pdfVersion>1.4</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>595.276 x 790.866 pts</pdfPageSize><refBibsNative>false</refBibsNative><abstractWordCount>245</abstractWordCount><abstractCharCount>1632</abstractCharCount><keywordCount>4</keywordCount></qualityIndicators><title>Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title><genre><json:string>research-article</json:string></genre><host><title>Clinical Rheumatology</title><language><json:string>unknown</json:string></language><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><issn><json:string>0770-3198</json:string></issn><eissn><json:string>1434-9949</json:string></eissn><journalId><json:string>10067</json:string></journalId><volume>31</volume><issue>11</issue><pages><first>1567</first><last>1575</last></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>SC11</value></json:item><json:item><value>Rheumatology</value></json:item></subject></host><ark><json:string>ark:/67375/VQC-PS6N8XWG-0</json:string></ark><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1007/s10067-012-2049-6</json:string></doi><id>71D2D40BFB93858AC2F628A3655E1297C173E8E5</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-PS6N8XWG-0/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-PS6N8XWG-0/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/VQC-PS6N8XWG-0/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">Springer-Verlag</publisher><pubPlace>London</pubPlace><availability><licence><p>Clinical Rheumatology, 2012</p></licence><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</p></availability><date>2012-05-12</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Original Article</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title><author xml:id="author-0000" corresp="yes"><persName><forename type="first">Rossana</forename><surname>Scrivo</surname></persName><email>rossana.scrivo@uniroma1.it</email><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Ilaria</forename><surname>Sauzullo</surname></persName><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Fabio</forename><surname>Mengoni</surname></persName><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Giancarlo</forename><surname>Iaiani</surname></persName><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Anna</forename><surname>Vestri</surname></persName><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Roberta</forename><surname>Priori</surname></persName><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Elisa</forename><surname>Di Filippo</surname></persName><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation></author><author xml:id="author-0007"><persName><forename type="first">Manuela</forename><surname>Di Franco</surname></persName><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Francesca</forename><surname>Spinelli</surname></persName><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Vincenzo</forename><surname>Vullo</surname></persName><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Claudio</forename><surname>Mastroianni</surname></persName><affiliation>UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza Università di Roma (Polo Pontino), Latina, Italy</affiliation></author><author xml:id="author-0011"><persName><forename type="first">Guido</forename><surname>Valesini</surname></persName><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation></author><idno type="istex">71D2D40BFB93858AC2F628A3655E1297C173E8E5</idno><idno type="ark">ark:/67375/VQC-PS6N8XWG-0</idno><idno type="DOI">10.1007/s10067-012-2049-6</idno><idno type="article-id">2049</idno><idno type="article-id">s10067-012-2049-6</idno></analytic><monogr><title level="j">Clinical Rheumatology</title><title level="j" type="sub">Journal of the International League of Associations for Rheumatology</title><title level="j" type="abbrev">Clin Rheumatol</title><idno type="pISSN">0770-3198</idno><idno type="eISSN">1434-9949</idno><idno type="journal-ID">true</idno><idno type="issue-article-count">17</idno><idno type="volume-issue-count">12</idno><imprint><publisher>Springer-Verlag</publisher><pubPlace>London</pubPlace><date type="published" when="2012-11-01"></date><biblScope unit="volume">31</biblScope><biblScope unit="issue">11</biblScope><biblScope unit="page" from="1567">1567</biblScope><biblScope unit="page" to="1575">1575</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012-05-12</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: Screening for latent tuberculosis infection (LTBI) prior to the prescribing of anti-TNF agents and monitoring for infection during treatment are recommended. The feasibility of novel screening tools, including QuantiFERON-TB Gold In-Tube (QFT-GIT), remains unclear in the setting of immunosuppression. The aim of this study was to evaluate the usefulness of serial QFT-GIT during biologic therapy to assess whether dynamic changes in IFN-γ levels may be helpful in identifying reactivation of LTBI or newly acquired TB. We conducted a prospective study on patient candidates to TNF inhibitors. QFT-GIT was performed at baseline and after 3 and 6 months since biologic onset. A further follow-up period of 6 months was observed. Among patients enrolled (n = 119; F = 69 %; median age = 47 years, range 18–80), 24 had at least 1 risk factor for LTBI. Ninety-six were taking immunosuppressants at the time of TB testing. At baseline, 5 patients displayed positive, 93 negative, and 21 indeterminate QFT-GIT results. We observed QFT-GIT conversions and reversions in 12 patients with LTBI and in 73 without LTBI. QFT-GIT results changed of 28 % at month 3 and of 21 % at month 6; the greatest change was observed in patients with indeterminate results that became negative (15 %; p < 0.02). No TB cases were detected. In conclusion, the routine use of both QFT-GIT and TST at screening seems not to give any advantage in the setting of patients awaiting biologics. In addition, the feasibility of serial QFT-GIT during biologic therapy needs definition since changes in IFN-γ levels may occur without a pathologic connotation.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Anti-TNF</term></item><item><term>QuantiFERON-TB Gold In-Tube</term></item><item><term>Rheumatoid arthritis</term></item><item><term>Tuberculin skin test</term></item></list></keywords></textClass><textClass><keywords scheme="Journal-Subject-Collection"><list><label>Medicine</label><item><term>SC11</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Medicine & Public Health</head><item><term>Rheumatology</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-05-12">Created</change><change when="2012-11-01">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-PS6N8XWG-0/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="corpus springer-journals not found" wicri:toSee="no header"><istex:xmlDeclaration>version="1.0" encoding="UTF-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//Springer-Verlag//DTD A++ V2.4//EN" URI="http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd" name="istex:docType"></istex:docType><istex:document><Publisher><PublisherInfo><PublisherName>Springer-Verlag</PublisherName><PublisherLocation>London</PublisherLocation></PublisherInfo><Journal OutputMedium="All"><JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered"><JournalID>10067</JournalID><JournalPrintISSN>0770-3198</JournalPrintISSN><JournalElectronicISSN>1434-9949</JournalElectronicISSN><JournalTitle>Clinical Rheumatology</JournalTitle><JournalSubTitle>Journal of the International League of Associations for Rheumatology</JournalSubTitle><JournalAbbreviatedTitle>Clin Rheumatol</JournalAbbreviatedTitle><JournalSubjectGroup><JournalSubject Type="Primary">Medicine & Public Health</JournalSubject><JournalSubject Type="Secondary">Rheumatology</JournalSubject><SubjectCollection Code="Medicine">SC11</SubjectCollection></JournalSubjectGroup></JournalInfo><Volume OutputMedium="All"><VolumeInfo TocLevels="0" VolumeType="Regular"><VolumeIDStart>31</VolumeIDStart><VolumeIDEnd>31</VolumeIDEnd><VolumeIssueCount>12</VolumeIssueCount></VolumeInfo><Issue IssueType="Regular" OutputMedium="All"><IssueInfo IssueType="Regular" TocLevels="0"><IssueIDStart>11</IssueIDStart><IssueIDEnd>11</IssueIDEnd><IssueArticleCount>17</IssueArticleCount><IssueHistory><OnlineDate><Year>2012</Year><Month>10</Month><Day>30</Day></OnlineDate><PrintDate><Year>2012</Year><Month>10</Month><Day>29</Day></PrintDate><CoverDate><Year>2012</Year><Month>11</Month></CoverDate><PricelistYear>2012</PricelistYear></IssueHistory><IssueCopyright><CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName><CopyrightYear>2012</CopyrightYear></IssueCopyright></IssueInfo><Article ID="s10067-012-2049-6" OutputMedium="All"><ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0"><ArticleID>2049</ArticleID><ArticleDOI>10.1007/s10067-012-2049-6</ArticleDOI><ArticleSequenceNumber>6</ArticleSequenceNumber><ArticleTitle Language="En">Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</ArticleTitle><ArticleCategory>Original Article</ArticleCategory><ArticleFirstPage>1567</ArticleFirstPage><ArticleLastPage>1575</ArticleLastPage><ArticleHistory><RegistrationDate><Year>2012</Year><Month>7</Month><Day>24</Day></RegistrationDate><Received><Year>2012</Year><Month>5</Month><Day>12</Day></Received><Revised><Year>2012</Year><Month>6</Month><Day>20</Day></Revised><Accepted><Year>2012</Year><Month>7</Month><Day>23</Day></Accepted><OnlineDate><Year>2012</Year><Month>8</Month><Day>5</Day></OnlineDate></ArticleHistory><ArticleCopyright><CopyrightHolderName>Clinical Rheumatology</CopyrightHolderName><CopyrightYear>2012</CopyrightYear></ArticleCopyright><ArticleGrants Type="Regular"><MetadataGrant Grant="OpenAccess"></MetadataGrant><AbstractGrant Grant="OpenAccess"></AbstractGrant><BodyPDFGrant Grant="Restricted"></BodyPDFGrant><BodyHTMLGrant Grant="Restricted"></BodyHTMLGrant><BibliographyGrant Grant="Restricted"></BibliographyGrant><ESMGrant Grant="Restricted"></ESMGrant></ArticleGrants></ArticleInfo><ArticleHeader><AuthorGroup><Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Rossana</GivenName><FamilyName>Scrivo</FamilyName></AuthorName><Contact><Phone>+39-06-49974631</Phone><Fax>+39-06-49974642</Fax><Email>rossana.scrivo@uniroma1.it</Email></Contact></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Ilaria</GivenName><FamilyName>Sauzullo</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Fabio</GivenName><FamilyName>Mengoni</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Giancarlo</GivenName><FamilyName>Iaiani</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Anna</GivenName><GivenName>Rita</GivenName><FamilyName>Vestri</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Roberta</GivenName><FamilyName>Priori</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Elisa</GivenName><Particle>Di</Particle><FamilyName>Filippo</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Manuela</GivenName><Particle>Di</Particle><FamilyName>Franco</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Francesca</GivenName><GivenName>Romana</GivenName><FamilyName>Spinelli</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff2"><AuthorName DisplayOrder="Western"><GivenName>Vincenzo</GivenName><FamilyName>Vullo</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff3"><AuthorName DisplayOrder="Western"><GivenName>Claudio</GivenName><GivenName>Maria</GivenName><FamilyName>Mastroianni</FamilyName></AuthorName></Author><Author AffiliationIDS="Aff1"><AuthorName DisplayOrder="Western"><GivenName>Guido</GivenName><FamilyName>Valesini</FamilyName></AuthorName></Author><Affiliation ID="Aff1"><OrgDivision>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia</OrgDivision><OrgName>Sapienza Università di Roma</OrgName><OrgAddress><Street>viale del Policlinico 155</Street><Postcode>00161</Postcode><City>Rome</City><Country Code="IT">Italy</Country></OrgAddress></Affiliation><Affiliation ID="Aff2"><OrgDivision>Dipartimento di Sanità Pubblica e Malattie Infettive</OrgDivision><OrgName>Sapienza Università di Roma</OrgName><OrgAddress><City>Rome</City><Country Code="IT">Italy</Country></OrgAddress></Affiliation><Affiliation ID="Aff3"><OrgDivision>UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci</OrgDivision><OrgName>Sapienza Università di Roma (Polo Pontino)</OrgName><OrgAddress><City>Latina</City><Country Code="IT">Italy</Country></OrgAddress></Affiliation></AuthorGroup><Abstract ID="Abs1" Language="En" OutputMedium="All"><Heading>Abstract</Heading><Para>Screening for latent tuberculosis infection (LTBI) prior to the prescribing of anti-TNF agents and monitoring for infection during treatment are recommended. The feasibility of novel screening tools, including QuantiFERON-TB Gold In-Tube (QFT-GIT), remains unclear in the setting of immunosuppression. The aim of this study was to evaluate the usefulness of serial QFT-GIT during biologic therapy to assess whether dynamic changes in IFN-γ levels may be helpful in identifying reactivation of LTBI or newly acquired TB. We conducted a prospective study on patient candidates to TNF inhibitors. QFT-GIT was performed at baseline and after 3 and 6 months since biologic onset. A further follow-up period of 6 months was observed. Among patients enrolled (<Emphasis Type="Italic">n</Emphasis> = 119; <Emphasis Type="Italic">F</Emphasis> = 69 %; median age = 47 years, range 18–80), 24 had at least 1 risk factor for LTBI. Ninety-six were taking immunosuppressants at the time of TB testing. At baseline, 5 patients displayed positive, 93 negative, and 21 indeterminate QFT-GIT results. We observed QFT-GIT conversions and reversions in 12 patients with LTBI and in 73 without LTBI. QFT-GIT results changed of 28 % at month 3 and of 21 % at month 6; the greatest change was observed in patients with indeterminate results that became negative (15 %; <Emphasis Type="Italic">p</Emphasis> < 0.02). No TB cases were detected. In conclusion, the routine use of both QFT-GIT and TST at screening seems not to give any advantage in the setting of patients awaiting biologics. In addition, the feasibility of serial QFT-GIT during biologic therapy needs definition since changes in IFN-γ levels may occur without a pathologic connotation.</Para></Abstract><KeywordGroup Language="En" OutputMedium="All"><Heading>Keywords</Heading><Keyword>Anti-TNF</Keyword><Keyword>QuantiFERON-TB Gold In-Tube</Keyword><Keyword>Rheumatoid arthritis</Keyword><Keyword>Tuberculin skin test</Keyword></KeywordGroup></ArticleHeader><NoBody></NoBody></Article></Issue></Volume></Journal></Publisher></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents</title></titleInfo><name type="personal" displayLabel="corresp"><namePart type="given">Rossana</namePart><namePart type="family">Scrivo</namePart><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation><affiliation>E-mail: rossana.scrivo@uniroma1.it</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ilaria</namePart><namePart type="family">Sauzullo</namePart><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabio</namePart><namePart type="family">Mengoni</namePart><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giancarlo</namePart><namePart type="family">Iaiani</namePart><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anna</namePart><namePart type="given">Rita</namePart><namePart type="family">Vestri</namePart><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Roberta</namePart><namePart type="family">Priori</namePart><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elisa</namePart><namePart type="family">Di Filippo</namePart><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Manuela</namePart><namePart type="family">Di Franco</namePart><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francesca</namePart><namePart type="given">Romana</namePart><namePart type="family">Spinelli</namePart><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vincenzo</namePart><namePart type="family">Vullo</namePart><affiliation>Dipartimento di Sanità Pubblica e Malattie Infettive, Sapienza Università di Roma, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Claudio</namePart><namePart type="given">Maria</namePart><namePart type="family">Mastroianni</namePart><affiliation>UOC Malattie Infettive, Fondazione Eleonora Lorillard Spencer Cenci, Sapienza Università di Roma (Polo Pontino), Latina, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Guido</namePart><namePart type="family">Valesini</namePart><affiliation>Dipartimento di Medicina Interna e Specialità Mediche, Reumatologia, Sapienza Università di Roma, viale del Policlinico 155, 00161, Rome, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="OriginalPaper" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>Springer-Verlag</publisher><place><placeTerm type="text">London</placeTerm></place><dateCreated encoding="w3cdtf">2012-05-12</dateCreated><dateIssued encoding="w3cdtf">2012-11-01</dateIssued><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><abstract lang="en">Abstract: Screening for latent tuberculosis infection (LTBI) prior to the prescribing of anti-TNF agents and monitoring for infection during treatment are recommended. The feasibility of novel screening tools, including QuantiFERON-TB Gold In-Tube (QFT-GIT), remains unclear in the setting of immunosuppression. The aim of this study was to evaluate the usefulness of serial QFT-GIT during biologic therapy to assess whether dynamic changes in IFN-γ levels may be helpful in identifying reactivation of LTBI or newly acquired TB. We conducted a prospective study on patient candidates to TNF inhibitors. QFT-GIT was performed at baseline and after 3 and 6 months since biologic onset. A further follow-up period of 6 months was observed. Among patients enrolled (n = 119; F = 69 %; median age = 47 years, range 18–80), 24 had at least 1 risk factor for LTBI. Ninety-six were taking immunosuppressants at the time of TB testing. At baseline, 5 patients displayed positive, 93 negative, and 21 indeterminate QFT-GIT results. We observed QFT-GIT conversions and reversions in 12 patients with LTBI and in 73 without LTBI. QFT-GIT results changed of 28 % at month 3 and of 21 % at month 6; the greatest change was observed in patients with indeterminate results that became negative (15 %; p < 0.02). No TB cases were detected. In conclusion, the routine use of both QFT-GIT and TST at screening seems not to give any advantage in the setting of patients awaiting biologics. In addition, the feasibility of serial QFT-GIT during biologic therapy needs definition since changes in IFN-γ levels may occur without a pathologic connotation.</abstract><note>Original Article</note><subject lang="en"><genre>Keywords</genre><topic>Anti-TNF</topic><topic>QuantiFERON-TB Gold In-Tube</topic><topic>Rheumatoid arthritis</topic><topic>Tuberculin skin test</topic></subject><relatedItem type="host"><titleInfo><title>Clinical Rheumatology</title><subTitle>Journal of the International League of Associations for Rheumatology</subTitle></titleInfo><titleInfo type="abbreviated"><title>Clin Rheumatol</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>Springer</publisher><dateIssued encoding="w3cdtf">2012-10-30</dateIssued><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><subject><genre>Journal-Subject-Collection</genre><topic authority="SpringerSubjectCodes" authorityURI="Medicine">SC11</topic></subject><subject><genre>Medicine & Public Health</genre><topic>Rheumatology</topic></subject><identifier type="ISSN">0770-3198</identifier><identifier type="eISSN">1434-9949</identifier><identifier type="JournalID">10067</identifier><identifier type="IssueArticleCount">17</identifier><identifier type="VolumeIssueCount">12</identifier><part><date>2012</date><detail type="volume"><number>31</number><caption>vol.</caption></detail><detail type="issue"><number>11</number><caption>no.</caption></detail><extent unit="pages"><start>1567</start><end>1575</end></extent></part><recordInfo><recordOrigin>Clinical Rheumatology, 2012</recordOrigin></recordInfo></relatedItem><identifier type="istex">71D2D40BFB93858AC2F628A3655E1297C173E8E5</identifier><identifier type="ark">ark:/67375/VQC-PS6N8XWG-0</identifier><identifier type="DOI">10.1007/s10067-012-2049-6</identifier><identifier type="ArticleID">2049</identifier><identifier type="ArticleID">s10067-012-2049-6</identifier><accessCondition type="use and reproduction" contentType="copyright">Clinical Rheumatology, 2012</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-3XSW68JL-F">springer</recordContentSource><recordOrigin>Clinical Rheumatology, 2012</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/VQC-PS6N8XWG-0/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002134 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002134 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:71D2D40BFB93858AC2F628A3655E1297C173E8E5
|texte= Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents
}}
| This area was generated with Dilib version V0.6.33. |  |